^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
03/10/2021
Excerpt:
Australian prescription medicine decision summary...Ruxience (rituximab) was approved for the following therapeutic use...Chronic lymphocytic leukaemia...Ruxience is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia (CLL) in combination with chemotherapy.
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
05/26/2020
Excerpt:
RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with...Chronic Lymphocytic Leukemia (CLL)...Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
Secondary therapy:
FC
Evidence Level:
Sensitive: A1 - Approval
Published date:
04/07/2020
Excerpt:
Ruxience is a medicine used in adults to treat the following blood cancers and inflammatory conditions....chronic lymphocytic leukaemia (CLL, another blood cancer affecting white blood cells)